Abbott's erythromycin caps
"The Pink Sheet" (Aug. 24, T&G-3) incorrectly reported that no generic version of Parke-Davis' ERYC has been approved. Abbott has been marketing since March an erythromycin 250 capsule product that is rated by FDA to be bioequivalent to the Parke-Davis product.
You may also be interested in...
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
After reviewing real-world data, the US agency says the decontamination systems should only be used for compatible facemasks and should not be used to clean a mask more than four times.
Under an extensive COVID-19 plan and executive order signed on 21 January, the US president explained how he’ll beef up testing and manufacturing of medtech to fight the virus.